ClinicalTrials.gg
RecruitingNCT07033494Updated Oct 20, 2026

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

A Phase 2 interventional study of MK-2214 and Placebo in Early Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Recruiting at 80 sites in 11 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 20, 2026Site recruiting status changedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.

Planned enrollment
5th of 29
340 · median 34
Started
2025
the only one that year
Phase 2
8 of 31
1 open now
Registered
31st of 31
by date

Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 5th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 2, and was the 31st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries.

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Alzheimer Disease by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.

The goals of the study are to learn:

  • If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
  • About the safety of MK-2214 and if people tolerate it
Read the detailed description

Per AM03, an optional open-label extension period has been added to the study.

03

Conditions studied

  • Early Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
  • Has a designated study partner who can fulfill the requirements of this study
  • If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a known history of stroke or cerebrovascular disease
  • Has diagnosis of a central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
  • Has structural brain disease
  • Has a history of seizures or epilepsy within 5 years before screening
  • Has any other major central nervous system trauma, or infections that affect brain function
  • Has major medical illness or unstable medical condition within 3 months before screening
  • Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
  • Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or during the study
  • Has a bleeding disorder that is not under adequate control
  • Has a history of occurring within 5 years of screening
  • Has a risk factor for interval (QTc) prolongation
  • Has liver disease
  • Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan
  • Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    Base and Open-Label Extension Period: MK-2214

    Participants will receive MK-2214 via intravenous (IV) infusion every 4 weeks (q4w) during the base period. After the completion of the base period participants have the option to continue receiving MK-2214 throughout the open-label extension period.

    Biological: MK-2214

  • Placebo comparator
    Base Period: Placebo

    Participants will receive a placebo via IV infusion q4w during the base period.

    Drug: Placebo

Interventions

  • BiologicalMK-2214

    IV infusion

  • DrugPlacebo

    IV infusion

06

What researchers measure

Primary outcomes

  1. Base Period: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr)

    Participants will have tau PET imaging to assess tau pathology. Tau is a protein that accumulates in AD \& damages brain cells. SUVr is SUV in the region of interest divided by SUV in a reference region (cerebellum). The change from baseline in tau PET SUVr will be reported.

    Time frame: Baseline, up to approximately 23 months

  2. Base Period: Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience one or more AEs will be reported.

    Time frame: Up to approximately 26 months

  3. Base Period: Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 23 months

Secondary outcomes

  1. Base Period: Change from Baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) Total Score

    The CDR-SB is used for cognitive assessment in people with AD. The CDR is a clinical scale that describes 5 degrees of impairment in performance on each of 6 categories of function including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The ratings of degree of impairment obtained on each of the 6 categories of function are synthesized into 1 global rating of dementia CDR score ranging from 0 (normal) to 3 (severe). A total score is calculated as the sum of the category scores, with a range of 0 (normal) to 18 (severe). Higher scores indicate more impairment. The change from baseline in CDR-SB total score will be reported.

    Time frame: Baseline, up to approximately 23 months

  2. Base Period: Change from Baseline in the Composite Tau PET SUVr in Braak Region III and IV

    Participants will have tau PET imaging to assess tau pathology. Tau is a protein that accumulates in AD \& damages brain cells. SUVr is SUV in the region of interest, divided by SUV in a reference region (cerebellum). Braak staging ranges from Braak I to VI. Description for Braak III includes amygdala, parahippocampal gyrus, fusiform gyrus, \& lingual gyrus, and Braak IV includes insula, inferior temporal, lateral temporal, posterior cingulate, \& inferior parietal. The composite tau PET SUVr is a weighted average of tau PET SUVr values obtained from multiple brain regions, with weights being the percentage volume of each region within the composite. The change from baseline in composite tau PET SUVr in Braak regions III and IV will be reported.

    Time frame: Baseline, up to approximately 23 months

  3. Base Period: Change from Baseline in the Composite Tau PET SUVr

    Participants will have tau PET imaging to assess tau pathology. Tau is a protein that accumulates in AD \& damages brain cells. SUVr is SUV in the region of interest, divided by SUV in a reference region (cerebellum). The composite tau PET SUVr is a weighted average of tau PET SUVr values obtained from multiple brain regions, with weights being the percentage volume of each region within the composite. The change from baseline in composite tau PET SUVr will be reported.

    Time frame: Baseline, up to approximately 23 months

  4. Base Period: Change from Baseline in the Composite Tau PET SUVr in Braak Region I to VI

    Participants will have tau PET imaging to assess tau (protein that accumulates in AD \& damages brain cells) pathology. SUVr is SUV in the region of interest, divided by SUV in a reference region (cerebellum). Braak staging ranges from I-VI (Braak I (transentorhinal); II (entorhinal \& hippocampus); III (amygdala, parahippocampal gyrus, fusiform gyrus, \& lingual gyrus); IV (insula, inferior temporal, lateral temporal, posterior cingulate, \& inferior parietal); V (orbitofrontal, superior temporal, inferior frontal, cuneus, anterior cingulate, supramarginal gyrus, lateral occipital, precuneus, superior parietal, superior frontal, \& rostro medial frontal); VI (paracentral, postcentral, precentral, \& pericalcarine)). Composite tau PET SUVr is weighted average of tau PET SUVr values from multiple brain regions, with weights being percentage volume of each region. The change from baseline in composite tau PET SUVr in Braak region I to IV will be reported.

    Time frame: Baseline, up to approximately 23 months

  5. Base Period: Change from Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale13 (ADAS-Cog13) Total Score

    The ADAS-Cog13 is a structured scale that evaluates memory (word recall, delayed word recall, and word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). In addition, ratings of spoken language, language comprehension, word finding difficulty, ability to remember test instructions, and number cancellation will be obtained. Per protocol, score range will be from 0 (no impairment) to 85 (maximum impairment) points. Higher scores indicate more impairment. The change from baseline in ADAS-Cog13 total score will be reported.

    Time frame: Baseline, up to approximately 23 months

  6. Base Period: Change from Baseline in the Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total Score

    ADCS-ADL-MCI evaluates the ability of individuals to perform various daily activities including basic activities of daily living (BADL; personal care tasks like bathing, dressing and eating) and instrumental activities of daily living (IADL; complex tasks such as managing finances, preparing meals, using telephone) administered through caregiver or family member to access severity of cognitive decline in the past 4 weeks. Each item is scored on a scale of 0 (unable to do) to 2 (independent). The total score is calculated by summing scores of all items and ranges from 0 (poor functioning) to 68 (better functioning). Higher scores indicate better functional ability. The change from baseline in ADCS-ADL-MCI total score will be reported.

    Time frame: Baseline, up to approximately 23 months

  7. Base Period: Change from Baseline in Modified Integrated Alzheimer's Disease Rating Scale (iADRS) Total Score

    The modified iADRS is a composite tool to measure cognition and function. The modified iADRS is a linear combination of total scores from the ADAS-Cog and the ADCS-ADL-MCI. The modified iADRS composite score is calculated by subtracting the ADAS-Cog13 score from 85 and then adding the ADCS-ADL-MCI score. Composite score ranges from 0 (maximum impairment) to 144 (greater independent, healthy functioning and cognition). Lower scores indicate more impairment. The change from baseline in modified iADRS total score will be reported.

    Time frame: Baseline, up to approximately 23 months

07

Study locations

79 of 80 sites recruiting
  • Irvine Clinical Research ( Site 1041)
    Irvine, California 92614, United States
    Recruiting
    • Study Coordinator · Contact949-753-1663
  • Healthy Brain Clinic ( Site 1005)
    Long Beach, California 90804, United States
    Recruiting
    • Study Coordinator · Contact562-606-5999
  • Inglewood Clinical ( Site 1062)
    Los Angeles, California 90056, United States
    Recruiting
    • Study Coordinator · Contact949-265-1612
  • Anderson Clinical Research ( Site 1024)
    Redlands, California 92374, United States
    Recruiting
    • Study Coordinator · Contact909-792-9007
  • UCSF Memory and Aging Center ( Site 1031)
    San Francisco, California 94158, United States
    Recruiting
    • Study Coordinator · Contact415-353-3585
  • Syrentis Clinical Research ( Site 1001)
    Santa Ana, California 92705, United States
    Recruiting
    • Study Coordinator · Contact714-542-3008
  • Yale University, Alzheimer's Disease Research Unit ( Site 1059)
    New Haven, Connecticut 06510, United States
    Recruiting
    • Study Coordinator · Contact203-764-8100
  • JEM Research Institute ( Site 1046)
    Atlantis, Florida 33462, United States
    Recruiting
    • Study Coordinator · Contact561-968-2933
  • Neuropsychiatric Research Center of Southwest Florida ( Site 1003)
    Fort Myers, Florida 33912, United States
    Recruiting
    • Study Coordinator · Contact239-939-7777
  • K2 Medical Research ( Site 1047)
    Maitland, Florida 32750, United States
    Recruiting
    • Study Coordinator · Contact407-500-5252
  • ClinCloud LLC ( Site 1039)
    Melbourne, Florida 32940, United States
    Recruiting
    • Study Coordinator · Contact407-680-0534
  • Indago Research and Health Center Inc ( Site 1044)
    Miami Lakes, Florida 33016, United States
    Recruiting
    • Study Coordinator · Contact305-825-6588
  • Aqualane Clinical Research ( Site 1035)
    Naples, Florida 34105, United States
    Recruiting
    • Study Coordinator · Contact239-529-6780
  • Suncoast Clinical Research ( Site 1007)
    New Port Richey, Florida 34652, United States
    Recruiting
    • Study Coordinator · Contact727-849-4131
  • Renstar Medical Research ( Site 1012)
    Ocala, Florida 34471, United States
    Recruiting
    • Study Coordinator · Contact352-629-5800
  • Charter Research - Orlando ( Site 1051)
    Orlando, Florida 32803, United States
    Recruiting
    • Study Coordinator · Contact407-337-3000
  • Axiom Brain Health ( Site 1029)
    Tampa, Florida 33609, United States
    Recruiting
    • Study Coordinator · Contact813-353-9613
  • K2 Medical Research ( Site 1020)
    Tampa, Florida 33634, United States
    Recruiting
    • Study Coordinator · Contact813-800-5252
  • Charter Research - Lady Lake ( Site 1019)
    The Villages, Florida 32162, United States
    Recruiting
    • Study Coordinator · Contact352-775-1000
  • Conquest Research LLC ( Site 1053)
    Winter Park, Florida 32789, United States
    Recruiting
    • Study Coordinator · Contact407-916-0060
  • CenExel iResearch, LLC ( Site 1015)
    Decatur, Georgia 30030, United States
    Recruiting
    • Study Coordinator · Contact404-537-1281
  • Alexian Brothers Medical Center-Neurosciences ( Site 1017)
    Elk Grove Village, Illinois 60007, United States
    Recruiting
    • Study Coordinator · Contact847-593-8553
  • Boston Center for Memory ( Site 1008)
    Newton, Massachusetts 02459, United States
    Recruiting
    • Study Coordinator · Contact617-699-6927
  • Clinical Research Professionals ( Site 1004)
    Chesterfield, Missouri 63005, United States
    Completed

    Not enrolling at this site — choose another above.

  • CenExel- AMRI ( Site 1018)
    Marlton, New Jersey 08053, United States
    Recruiting
    • Study Coordinator · Contact732-341-9500
  • The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064)
    Ridgewood, New Jersey 07450, United States
    Recruiting
    • Study Coordinator · Contact201-850-4622
  • The Cognitive and Research Center of NJ ( Site 1057)
    Springfield, New Jersey 07081, United States
    Recruiting
    • Study Coordinator · Contact973-850-4622
  • Alzheimer Disease Research Center (ADRC) ( Site 1000)
    Albany, New York 12208, United States
    Recruiting
    • Study Coordinator · Contact518-426-0575
  • Mid Hudson Medical Research ( Site 1050)
    New Windsor, New York 12553, United States
    Recruiting
    • Study Coordinator · Contact845-674-9398
  • Basil Clinical ( Site 1065)
    Queens, New York 11413, United States
    Recruiting
    • Study Coordinator · Contact917-672-3275
  • AMC Research, LLC ( Site 1006)
    Matthews, North Carolina 28105, United States
    Recruiting
    • Study Coordinator · Contact704-364-4000
  • Insight Clinical Trials ( Site 1011)
    Independence, Ohio 44131, United States
    Recruiting
    • Study Coordinator · Contact216-245-6556
  • Neuro-Behavioral Clinical Research ( Site 1028)
    North Canton, Ohio 44720, United States
    Recruiting
    • Study Coordinator · Contact330-493-1118
  • Flourish Research ( Site 1048)
    Plymouth Meeting, Pennsylvania 19462, United States
    Recruiting
    • Study Coordinator · Contact610-277-8073
  • Gadolin Research ( Site 1032)
    Beaumont, Texas 77702, United States
    Recruiting
    • Study Coordinator · Contact409-331-6040
  • Horizon Clinical Research Center - Houston ( Site 1026)
    Cypress, Texas 77429, United States
    Recruiting
    • Study Coordinator · Contact949-491-0710
  • Organizacion Medica de Investigacion ( Site 0401)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1015ABO, Argentina
    Recruiting
    • Study Coordinator · Contact+5491143720308
  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0404)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1431FWO, Argentina
    Recruiting
    • Study Coordinator · Contact+5401152990000
  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) ( Site 0400)
    Caba, C1428AQK, Argentina
    Recruiting
    • Study Coordinator · Contact+541157773200
  • Southern Neurology ( Site 0306)
    Kogarah, New South Wales 2217, Australia
    Recruiting
    • Study Coordinator · Contact+61408455183
  • KARA Institute for Neurological Diseases ( Site 0302)
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
    • Study Coordinator · Contact+61289607788
  • Austin Health ( Site 0300)
    Ivanhoe, Victoria 3079, Australia
    Recruiting
    • Study Coordinator · Contact61394962181
  • HammondCare ( Site 0301)
    Malvern, Victoria 3144, Australia
    Recruiting
    • Study Coordinator · Contact+61395976568
  • Cliniques universitaires Saint-Luc ( Site 3001)
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
    Recruiting
    • Study Coordinator · Contact+3227641779
  • UZ Leuven ( Site 3000)
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 16 34 75 90
  • AZ Groeninge Campus Kennedylaan ( Site 3002)
    Kortrijk, West-Vlaanderen 8500, Belgium
    Recruiting
    • Study Coordinator · Contact+3256636363
  • Ottawa Memory Clinic ( Site 2001)
    Ottawa, Ontario K1Z 1G3, Canada
    Recruiting
    • Study Coordinator · Contact613-702-1000
  • Sunnybrook Research Institute ( Site 2003)
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Study Coordinator · Contact4164804551
  • Toronto Western Hospital ( Site 2004)
    Toronto, Ontario M5T 2S8, Canada
    Recruiting
    • Study Coordinator · Contact4166032581
  • Clinique Mémoire de Montreal ( Site 2000)
    Montreal, Quebec H3G 1H9, Canada
    Recruiting
    • Study Coordinator · Contact5144003903
  • National Center for Geriatrics and Gerontology ( Site 9002)
    Ōbu, Aichi-ken 474-8511, Japan
    Recruiting
    • Study Coordinator · Contact+81-562-46-2311
  • Chibaken Saiseikai Narashino Hospital ( Site 9000)
    Narashino, Chiba 275-8580, Japan
    Recruiting
    • Study Coordinator · Contact+81-47-473-1281
  • Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 9016)
    Kawasaki, Kanagawa 210-0852, Japan
    Recruiting
    • Study Coordinator · Contact+81-44-366-8900
  • Mie University Hospital ( Site 9011)
    Tsu, Mie-ken 514-8507, Japan
    Recruiting
    • Study Coordinator · Contact+81-59-231-5246
  • Katayama Medical Clinic ( Site 9005)
    Kurashiki, Okayama-ken 710-0813, Japan
    Recruiting
    • Study Coordinator · Contact+81-86-422-0753
  • Hatsuta Neurology Clinic ( Site 9017)
    Hirakata, Osaka 573-1121, Japan
    Recruiting
    • Study Coordinator · Contact+81-72-850-8692
  • National Hospital Organization Hizen Psychiatric Medical Center ( Site 9004)
    Kanzaki-gun, Saga-ken 8420192, Japan
    Recruiting
    • Study Coordinator · Contact+81-952-52-3231
  • Tokyo Medical University Hospital ( Site 9003)
    Shinjuku, Tokyo 160-0023, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3342-6111
  • Inage Neurology and Memory Clinic ( Site 9001)
    Chiba, 263-0043, Japan
    Recruiting
    • Study Coordinator · Contact+81-43-307-8500
  • Kyushu University Hospital ( Site 9010)
    Fukuoka, 812-8582, Japan
    Recruiting
    • Study Coordinator · Contact+81-92-642-5774
  • Okayama City General Medical Center Okayama City Hospital ( Site 9008)
    Okayama, 700-8557, Japan
    Recruiting
    • Study Coordinator · Contact+81-86-737-3000
  • Brain Research Center Den Bosch B.V. ( Site 5001)
    's-Hertogenbosch, North Brabant 5223 LA, Netherlands
    Recruiting
    • Study Coordinator · Contact+0203017170
  • Brain Research Center. ( Site 5000)
    Amsterdam, North Holland 1081 GN, Netherlands
    Recruiting
    • Study Coordinator · Contact+0203017170
  • Brain Research Center Zwolle ( Site 5002)
    Zwolle, Overijssel 8025 AZ, Netherlands
    Recruiting
    • Study Coordinator · Contact+0203017170
  • National Neuroscience Institute ( Site 0101)
    Singapore, Central Singapore 308433, Singapore
    Recruiting
    • Study Coordinator · Contact'+6563306363
  • Tan Tock Seng Hospital ( Site 0102)
    Singapore, Central Singapore 308433, Singapore
    Recruiting
    • Study Coordinator · Contact+6562566011
  • Hanyang University Hospital ( Site 0200)
    Seoul, 04763, South Korea
    Recruiting
    • Study Coordinator · Contact+82222908374
  • Samsung Medical Center ( Site 0202)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82234101233
  • Ewha Womans University Seoul Hospital ( Site 0201)
    Seoul, 07804, South Korea
    Recruiting
    • Study Coordinator · Contact+82269861792
  • Hospital Universitari Mutua Terrassa ( Site 6004)
    Terrassa, Barcelona 08222, Spain
    Recruiting
    • Study Coordinator · Contact+34937365050
  • Fundació ACE ( Site 6003)
    Barcelona, Catalonia 08028, Spain
    Recruiting
    • Study Coordinator · Contact+34677440680
  • Hospital del Mar ( Site 6001)
    Barcelona, 08003, Spain
    Recruiting
    • Study Coordinator · Contact+34933160778
  • Hospital Clinic i Provincial ( Site 6002)
    Barcelona, 08036, Spain
    Recruiting
    • Study Coordinator · Contact+34626001165
  • Scottish Brain Sciences Aberdeen ( Site 8001)
    Aberdeen, Aberdeen City AB25 2XE, United Kingdom
    Recruiting
    • Study Coordinator · Contact+4401313530233
  • Scottish Brain Sciences ( Site 8000)
    Edinburgh, Edinburgh, City of EH12 5PJ, United Kingdom
    Recruiting
    • Study Coordinator · Contact+4401313530233
  • Moorgreen Hospital ( Site 8004)
    Southampton, Hampshire SO30 3JB, United Kingdom
    Recruiting
    • Study Coordinator · Contact+44 (0) 2382318757
  • Leonard Wolfson Experimental Neurology Centre (LWENC) ( Site 8006)
    London, London, City of NW1 2PG, United Kingdom
    Recruiting
    • Study Coordinator · Contact020 3448 4531
  • Warneford Hospital ( Site 8007)
    Oxford, Oxfordshire OX3 7JX, United Kingdom
    Recruiting
    • Study Coordinator · Contact+441865902135
  • Remind UK ( Site 8003)
    Bath, Somerset BA1 3NG, United Kingdom
    Recruiting
    • Study Coordinator · Contact01225 476420
  • Re:Cognition Health - Birmingham ( Site 8002)
    Birmingham, B16 8LT, United Kingdom
    Recruiting
    • Study Coordinator · Contact0121 655 016
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2029, 45 months after the start.

Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 45 months is above that.

Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2029 → Apr 2030, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jun 24, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2030was Apr 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. Clinical Research Professionals ( Site 1004) is now Completed
Show site
  • CenExel- AMRI ( Site 1018) · Marlton, United States
Show 1 removed
  • CenExel- AMRI ( Site 1018) · Toms River, United States
Oct 20, 2026
Study completion
Apr 30, 2029→Apr 30, 2030
Oct 8, 2026
Interventions
Arm changed MK-2214→Base and Open-Label Extension Period: MK-2214; Placebo→Base Period: Placebo
Oct 8, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedBase Period: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr)Time frame: Baseline, up to approximately 23 months
  • EditedBase Period: Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 26 months
  • EditedBase Period: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 23 months
Oct 8, 2026
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedBase Period: Change from Baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) Total ScoreTime frame: Baseline, up to approximately 23 months
  • EditedBase Period: Change from Baseline in the Composite Tau PET SUVr in Braak Region III and IVTime frame: Baseline, up to approximately 23 months
  • EditedBase Period: Change from Baseline in the Composite Tau PET SUVrTime frame: Baseline, up to approximately 23 months
  • EditedBase Period: Change from Baseline in the Composite Tau PET SUVr in Braak Region I to VITime frame: Baseline, up to approximately 23 months
  • EditedBase Period: Change from Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale13 (ADAS-Cog13) Total ScoreTime frame: Baseline, up to approximately 23 months
  • EditedBase Period: Change from Baseline in the Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total ScoreTime frame: Baseline, up to approximately 23 months
  • EditedBase Period: Change from Baseline in Modified Integrated Alzheimer's Disease Rating Scale (iADRS) Total ScoreTime frame: Baseline, up to approximately 23 months
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Clinical Research Professionals ( Site 1004) · Chesterfield, United StatesContact removed •••1200
Oct 20, 2026
Show all 2 updates
  1. Oct 20, 2026
    1 site added, 1 site removed. Clinical Research Professionals ( Site 1004) is now Completed
    Show site
    • CenExel- AMRI ( Site 1018) · Marlton, United States
    Show 1 removed
    • CenExel- AMRI ( Site 1018) · Toms River, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Clinical Research Professionals ( Site 1004) · Chesterfield, United StatesContact removed •••1200
    + 1 other change: verification date
  2. Oct 8, 2026
    Study completion Apr 30, 2029→Apr 30, 2030
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedBase Period: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr)Time frame: Baseline, up to approximately 23 months
    • EditedBase Period: Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 26 months
    • EditedBase Period: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 23 months
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedBase Period: Change from Baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) Total ScoreTime frame: Baseline, up to approximately 23 months
    • EditedBase Period: Change from Baseline in the Composite Tau PET SUVr in Braak Region III and IVTime frame: Baseline, up to approximately 23 months
    • EditedBase Period: Change from Baseline in the Composite Tau PET SUVrTime frame: Baseline, up to approximately 23 months
    • EditedBase Period: Change from Baseline in the Composite Tau PET SUVr in Braak Region I to VITime frame: Baseline, up to approximately 23 months
    • EditedBase Period: Change from Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale13 (ADAS-Cog13) Total ScoreTime frame: Baseline, up to approximately 23 months
    • EditedBase Period: Change from Baseline in the Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total ScoreTime frame: Baseline, up to approximately 23 months
    • EditedBase Period: Change from Baseline in Modified Integrated Alzheimer's Disease Rating Scale (iADRS) Total ScoreTime frame: Baseline, up to approximately 23 months
    Interventions Arm changed MK-2214→Base and Open-Label Extension Period: MK-2214; Placebo→Base Period: Placebo
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07033494
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Jul 16, 2025
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Oct 20, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion